Funding and declaration of interest:
The study acquired funding from the European Union’s Horizon 2020 research and innovation programme CURE under grant agreement No 767015, and the European FP7-Health programme PREDICTA under Grant agreement ID: 260895. CURE: “Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma”. PREDICTA: “Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases”. Disclaimer of EU responsibility: The content of this publication reflects only the views of its authors. The European Commission is not responsible for any use that may be made of the information it contains.